Scarica l'app Stockscreener
18.64
0.05%
0.01
Dopo l'orario di chiusura:
18.70
0.06
+0.32%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$18.63
Aprire:
$18.59
Volume 24 ore:
270.61K
Relative Volume:
0.06
Capitalizzazione di mercato:
$1.03B
Reddito:
$29.71M
Utile/perdita netta:
$-69.15M
Rapporto P/E:
-19.22
EPS:
-0.97
Flusso di cassa netto:
$-52.28M
1 W Prestazione:
+1.97%
1M Prestazione:
-4.41%
6M Prestazione:
+50,008%
1 anno Prestazione:
+50,008%
Intervallo 1D:
$18.15
$19.41
Intervallo di 1 settimana:
$16.88
$19.41
Portata 52W:
$16.80
$29.16
Aktis Oncology Inc Stock (AKTS) Company Profile
Nome
Aktis Oncology Inc
Settore
Industria
Telefono
-
Indirizzo
-
Compare AKTS vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AKTS
Aktis Oncology Inc
|
18.64 | 1.03B | 29.71M | -69.15M | -52.28M | -0.97 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Aktis Oncology Inc Stock (AKTS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-09 | Iniziato | H.C. Wainwright | Buy |
| 2026-02-03 | Iniziato | BofA Securities | Buy |
| 2026-02-03 | Iniziato | JP Morgan | Overweight |
| 2026-02-03 | Iniziato | Leerink Partners | Outperform |
| 2026-02-03 | Iniziato | TD Cowen | Buy |
| 2024-01-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-09-06 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2023-01-24 | Iniziato | B. Riley Securities | Buy |
| 2021-02-02 | Reiterato | Craig Hallum | Buy |
| 2021-01-15 | Reiterato | Craig Hallum | Buy |
| 2019-09-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2019-07-10 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2019-05-13 | Reiterato | Craig Hallum | Buy |
| 2019-02-05 | Reiterato | Craig Hallum | Buy |
| 2019-02-05 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2018-12-18 | Iniziato | Craig Hallum | Buy |
| 2018-11-30 | Iniziato | Lake Street | Buy |
| 2018-06-22 | Iniziato | Loop Capital | Buy |
| 2018-02-09 | Iniziato | Drexel Hamilton | Buy |
Mostra tutto
Aktis Oncology Inc Borsa (AKTS) Ultime notizie
This Aktis Oncology analyst begins coverage on a bullish note; here are top 5 initiations for Monday - MSN
Aktis Oncology, Inc.(NasdaqGS: AKTS) added to S&P TMI Index - marketscreener.com
Aktis Oncology, Inc.(NasdaqGS: AKTS) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
Huge insider buying now at this insurance giant and 2 biotechs - MSN
Aktis Oncology (AKTS) Stock Analysis Report | Financials & Insights - Benzinga Japan
Little-known Cambridge firm plans public debut to fund pancreatic cancer trial - The Business Journals
Analysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX), Contineum Therapeutics, Inc. Class A (CTNM) and Aktis Oncology, Inc. (AKTS) - The Globe and Mail
AKTS: Innovative radiopharmaceutical platform advances with strong pipeline, partnerships, and cash runway - TradingView
AKTS: Innovative radiopharmaceutical platform targets major cancer types, backed by strong pipeline and funding - TradingView
This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Aktis Oncology Fast Track Win Highlights AKY-1189 Potential And Key Risks - Sahm
Assessing Aktis Oncology (AKTS) Valuation After Recent Share Price Momentum And Ongoing Losses - Sahm
Aktis Oncology, Inc. (AKTS) Presents at TD Cowen 46th Annual Health Care ConferenceSlideshow - Seeking Alpha
Aktis Oncology’s NECTINIUM-2 Trial: A New Radiopharma Bet in Solid Tumors - TipRanks
AKTS: New miniprotein radiopharmaceuticals target broad solid tumor markets, advancing in clinic - TradingView
AKTS: Lead radiopharmaceutical assets advance toward major milestones in a rapidly expanding market - TradingView
BUDA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
AKTS Technical Analysis & Stock Price Forecast - Intellectia AI
IPO Tracker 2026: Generate Clocks Largest IPO Since 2024 With $400M Raise - BioSpace
Assessing Aktis Oncology (AKTS) Valuation As Shares Show Short Term Momentum Rebound - Yahoo Finance
Aktis Oncology: Fast-Track Momentum and Pipeline Catalysts Underpin Buy Rating and $34 Price Target - TipRanks
Aktis Oncology to Present at Upcoming March Investor Conferences - The Manila Times
Aktis Oncology (AKTS) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $AKTS - MarketBeat
Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate - Bitget
Aktis Oncology receives U.S. FDA fast track designation for Aky-1189 - marketscreener.com
FDA OKs Fast Track to AKY-1189 in Metastatic Urothelial Cancer - Cure Today
Flagship-Backed Generate Bio Seeks $425 Million in US IPO - Bloomberg.com
Flagship-Backed Generate Biomedicines Seeks $425 Million in IPO - Bloomberg.com
Flagship-backed Generate Biomedicines eyes $2.2 billion valuation in US IPO - Reuters
Ken Herrmann Net Worth (2026) - GuruFocus
US Index IPO ForecastMar26: 8 Additions Including Medline & BETA Technologies - Smartkarma
2026 kicks off with $10.8B January financing haul - BioWorld MedTech
Merck veteran Perlmutter-led Eikon Therapeutics valued at $860 million in Nasdaq debut - WTVB
Eikon’s $381M raise represents largest biopharma IPO in two years - BioWorld MedTech
Eikon Therapeutics raises $381M in IPO - Axios
Merck Veteran-Led Eikon Therapeutics Raises $381 Million in IPO - Bloomberg.com
Biopharma Co.'s Down-Round IPO May Signal More To Come - Law360
This GCI Liberty Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday - Benzinga
Aktis Oncology: Differentiated Miniprotein Radiopharma Platform Underpins Buy Rating and Multi-Billion Dollar Sales Potential - TipRanks
Merck veteran Perlmutter-led Eikon Therapeutics eyes $908 million valuation in IPO - Reuters
Eikon ?Therapeutics targets $908 million valuation in US IPO - marketscreener.com
Eikon sets $274M goal for upcoming stock market debut - Fierce Biotech
Carvina Capital: Strong Demand Lifts Aktis IPO - Barchart.com
Aktis Oncology prices IPO at $18 per share - MSN
Why Revolution Medicines Stock Surged by 11% Today - AOL.com
Huge Insider Buying Now at This Insurance Giant and 2 Biotechs - AOL.com
Investors Scoop Up Shares in Key Insurance and Biotech Companies - finance.coin-turk.com
‘No reasons to own’: Software stocks sink on fear of new AI tool - The Japan Times
Aktis Oncology Inc Azioni (AKTS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):